Pharma Lobby Ousts 22 Drugmakers Amid U.S. Pricing Debate
- Changes require minimum spending levels on R&D activities
- Jazz, Horizon are among companies no longer with the group
Trump vs. Big Pharma: Can He Bring Drug Prices Down?
This article is for subscribers only.
The pharmaceutical industry’s powerful Washington trade association fell in size by almost two dozen companies after revising membership rules amid the debate over U.S. drug prices.
Pharmaceutical Research and Manufacturers of America, or PhRMA, will require that members spend at least $200 million a year on research and development and that their R&D spending is at least 10 percent of global sales. The changes, reported by Bloomberg Sunday, follow a three-month review that has already seen several member companies leave the lobbying group.